Ondansetron Augmentation in Treatment Resistant Obsessive Compulsive Disorder: A Preliminary Single-Blind Prospective Study.
Phase of Trial: Phase IV
Latest Information Update: 23 Feb 2011
At a glance
- Drugs Ondansetron (Primary)
- Indications Obsessive-compulsive disorders
- Focus Therapeutic Use
- 01 Dec 2009 Results published in CNS Drugs.
- 21 May 2009 Status changed from recruiting to completed, according to a Transcept Pharmaceuticals media release.
- 21 May 2009 Results will be presented in a poster at the annual meetng of the American Psychiatric Association (APA), according to a Transcept Pharmaceuticals media release.